VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
---|---|---|---|---|---|---|---|---|
TVIS44015550 | HTLV-1 | ENSG00000203747.13 | protein_coding | FCGR3A | No | No | 2214 | P08637 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
Gene | FCGR3A |
---|---|
DrugBank ID | DB12023 |
Drug Name | Benralizumab |
Target ID | BE0002097 |
UniProt ID | P08637 |
Regulation Type | binding |
PubMed IDs | 22136436; 23866823; 28109128 |
Citations | Ghazi A, Trikha A, Calhoun WJ: Benralizumab--a humanized mAb to IL-5Ralpha with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012 Jan;12(1):113-8. doi: 10.1517/14712598.2012.642359. Epub 2011 Dec 5.@@Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V, Kolbeck R, Molfino NA: Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013 Nov;132(5):1086-1096.e5. doi: 10.1016/j.jaci.2013.05.020. Epub 2013 Jul 16.@@Wang B, Yan L, Yao Z, Roskos LK: Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma. CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):249-257. doi: 10.1002/psp4.12160. Epub 2017 Jan 21. |
Groups | Approved; Investigational |
Direct Classification | Peptides |
SMILES | |
Pathways | |
PharmGKB | |
ChEMBL |